- Topic1/3
15k Popularity
416 Popularity
3k Popularity
14k Popularity
18k Popularity
- Pin
- #Gate 2025 Semi-Year Community Gala# voting is in progress! 🔥
Gate Square TOP 40 Creator Leaderboard is out
🙌 Vote to support your favorite creators: www.gate.com/activities/community-vote
Earn Votes by completing daily [Square] tasks. 30 delivered Votes = 1 lucky draw chance!
🎁 Win prizes like iPhone 16 Pro Max, Golden Bull Sculpture, Futures Voucher, and hot tokens.
The more you support, the higher your chances!
Vote to support creators now and win big!
https://www.gate.com/announcements/article/45974
- 🎉 Hey Gate Square friends! Non-stop perks and endless excitement—our hottest posting reward events are ongoing now! The more you post, the more you win. Don’t miss your exclusive goodies! 🚀
1️⃣ #ETH Hits 4800# | Market Analysis & Prediction: Boldly share your ETH predictions to showcase your insights! 10 lucky users will split a 0.1 ETH prize!
Details 👉 https://www.gate.com/post/status/12322612
2️⃣ #Creator Campaign Phase 2# |ZKWASM Topic: Share original content about ZKWASM or its trading activity on X or Gate Square to win a share of 4,000 ZKWASM!
Details 👉 https://www.gate.com/post/st
Innovent Biologics: Positive Results from Phase II Clinical Trial of Innovative Drug ICP-488
Jinshi data news on October 9th, Norcheng Jianhua announced in the evening that the company's innovative drug ICP-488 achieved positive clinical trial results in a phase II randomized, double-blind, placebo-controlled study in patients with moderate to severe plaque psoriasis. The results showed that patients treated with 6mg and 9mg (once daily) of ICP-488 had significant improvement in PASI75 at week 12 compared to patients receiving placebo. In addition, the proportion of patients receiving ICP-488 treatment who achieved PASI90, PASI100, and static Physician Global Assessment (sPGA) 0/1 (i.e., complete or near-complete clearance of skin lesions) was significantly higher than that in the placebo group.